JOLEEN LESZCZYNSKI: Open Payments
NPI 1508538778 · LAS CRUCES, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,482 in 70 payments from 11 companies in 2025. Trend: 2023 $1,974 · 2024 $1,977 · 2025 $1,482
Food & beverage: $1,482
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $625 |
| GlaxoSmithKline, LLC. | 15 | $238 |
| Grifols USA, LLC | 9 | $173 |
| Viatris Specialty LLC | 7 | $160 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $93 |
| Verona Pharma, Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| GENZYME CORPORATION | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
Products named: FASENRA, BREZTRI, Prolastin-C Liquid, YUPELRI, NUCALA, AIRSUPRA, TRELEGY ELLIPTA, DUPIXENT.
Industry payments across NM — which companies pay providers there.
